Corrigendum to: Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster
1 Liverna Therapeutics Inc., Zhuhai 519000, Guangdong, China
2 State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510182, Guangdong, China
3 Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Hunan Normal University, Changsha 410005, Hunan, China
4 AIM Vaccine Co., Ltd., Beijing 100022, China
5 Hunan Provincial Center for Disease Prevention and Control, Changsha 410153, Hunan, China
6 Guangzhou Customs District Technology Center, Guangzhou 510623, Guangdong, China
7 Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, Shanghai Tech University, Shanghai 201210, China
8 Institute of Infectious disease, Guangzhou Eighth People’s Hospital of Guangzhou Medical University, Guangzhou 510442, Guangdong, China
9 Guangzhou National Laboratory, No. 9 XingDaoHuanBei Road, Guangzhou International Bio Island, Guangzhou 510005, Guangdong, China
10 Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong, China
Show less
PDF
(684KB)
